盈利预期调整

Search documents
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-12 22:10
分组1 - Arcturus Therapeutics reported a quarterly loss of $0.52 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.58, representing an earnings surprise of 67.09% [1] - The company posted revenues of $29.38 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.10%, but down from $38.01 million year-over-year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped revenue estimates twice [2] 分组2 - The stock has underperformed, losing about 35.3% since the beginning of the year, compared to a decline of 3.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.77 on revenues of $21.84 million, and for the current fiscal year, it is -$6.44 on revenues of $96.5 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-12 22:10
Financial Performance - Quanterix Corporation reported a quarterly loss of $0.53 per share, better than the Zacks Consensus Estimate of a loss of $0.69, but worse than a loss of $0.26 per share a year ago, indicating an earnings surprise of 23.19% [1] - The company posted revenues of $30.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.99%, although this is a decline from year-ago revenues of $32.07 million [2] - Over the last four quarters, Quanterix has surpassed consensus revenue estimates three times [2] Stock Performance - Quanterix shares have declined approximately 50.3% since the beginning of the year, compared to a decline of 3.8% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $30.83 million, and for the current fiscal year, it is -$1.62 on revenues of $138.32 million [7] Industry Outlook - The Medical - Products industry, to which Quanterix belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Quanterix's stock performance [5]
Atlanta Braves Holdings, Inc. (BATRA) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-12 14:05
Group 1 - Atlanta Braves Holdings, Inc. reported a quarterly loss of $0.66 per share, which was better than the Zacks Consensus Estimate of a loss of $0.94, and an improvement from a loss of $0.83 per share a year ago, resulting in an earnings surprise of 29.79% [1] - The company posted revenues of $47.21 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 34.12%, compared to revenues of $37.08 million in the same quarter last year [2] - The stock has increased approximately 6.6% since the beginning of the year, while the S&P 500 has declined by 3.8% [3] Group 2 - The earnings outlook for Atlanta Braves Holdings, Inc. is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $285.5 million, and for the current fiscal year, it is -$0.60 on revenues of $669 million [7] - The Media Conglomerates industry, to which Atlanta Braves Holdings, Inc. belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]
NRG Energy (NRG) Beats Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-12 13:25
NRG Energy (NRG) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $1.80 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 45.56%. A quarter ago, it was expected that this power company would post earnings of $0.95 per share when it actually produced earnings of $1.52, delivering a surprise of 60%.Over the last four quarters, the company has ...
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-12 13:15
Company Performance - BioXcel Therapeutics reported a quarterly loss of $1.50 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.72, and an improvement from a loss of $13.92 per share a year ago, resulting in an earnings surprise of 44.85% [1] - The company posted revenues of $0.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 44%, and down from $0.58 million in the same quarter last year [2] - Over the last four quarters, BioXcel has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - BioXcel Therapeutics shares have declined approximately 74.4% since the beginning of the year, contrasting with the S&P 500's decline of 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.24 on revenues of $0.4 million, and for the current fiscal year, it is -$16.44 on revenues of $3.51 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which BioXcel belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-12 13:15
Company Performance - Tango Therapeutics reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.35 per share a year ago, indicating an earnings surprise of -5.88% [1] - The company posted revenues of $5.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 13.94%, and down from $6.47 million in the same quarter last year [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Tango Therapeutics shares have declined approximately 63.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $5.72 million, and for the current fiscal year, it is -$1.37 on revenues of $28.53 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of ranked industries [8] - The performance of Tango Therapeutics may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-12 12:35
分组1 - ImmunityBio reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.12, but an improvement from a loss of $0.20 per share a year ago, indicating a surprise of -25% [1] - The company posted revenues of $16.52 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.25%, and showing a significant increase from revenues of $0.04 million in the same quarter last year [2] - ImmunityBio shares have declined approximately 19.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] 分组2 - The earnings outlook for ImmunityBio is mixed, with the current consensus EPS estimate for the coming quarter at -$0.12 on revenues of $21.11 million, and -$0.44 on revenues of $93.87 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which ImmunityBio belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-12 12:10
Company Performance - Aurinia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, compared to a loss of $0.03 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $62.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.63%, and showing an increase from year-ago revenues of $50.3 million [2] - Over the last four quarters, Aurinia has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - Aurinia shares have declined approximately 10.9% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $64.76 million, and for the current fiscal year, it is $0.44 on revenues of $258.28 million [7] Industry Context - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
ZACKS· 2025-05-09 23:30
Company Performance - Acadia Pharmaceuticals reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.10 per share a year ago [1] - The quarterly report reflects an earnings surprise of 10%, with GAAP EPS reported at 86 cents [2] - The company posted revenues of $244.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.23% and increasing from $205.83 million year-over-year [3] Market Position - Acadia shares have declined approximately 20.8% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $262.31 million, and for the current fiscal year, it is $0.68 on revenues of $1.06 billion [8] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [6]
TeraWulf Inc. (WULF) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-09 13:30
TeraWulf Inc. (WULF) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -128.57%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.08, delivering a surprise of -100%.Over the last four quarters, the company has not been ...